Ads
related to: new drug for essential tremor
Search results
Results From The WOW.Com Content Network
Ulixacaltamide is an investigational new drug developed by Praxis Precision Medicines, designed to treat essential tremor, [1] a common neurological disorder characterized by involuntary rhythmic shaking.
Essential tremor (ET), also called benign tremor, familial tremor, and idiopathic tremor, is a medical condition characterized by involuntary rhythmic contractions and relaxations (oscillations or twitching movements) of certain muscle groups in one or more body parts of unknown cause. [6]
The drug, called suvecaltamide, was being tested in adults with essential tremor, a condition that affects the nervous system and causes involuntary and rhythmic shaking, affecting about 10 ...
Primidone is not indicated for essential tremor but is often used as a first-line therapy for essential tremor, as is propranolol. In tremor amplitude reduction, it is just as effective as propranolol, reducing it by 50%. Both drugs are well studied for this condition, unlike other therapies, and are recommended for initial treatment.
Trihexyphenidyl (THP, benzhexol, trihex, marketed as Artane and others) is an antispasmodic drug used to treat stiffness, tremors, spasms, and poor muscle control. It is an agent of the antimuscarinic class and is often used in management of Parkinson's disease.
Befiradol (F-13,640; NLX-112) is an experimental drug being studied for the treatment of levodopa-induced dyskinesia. It is a potent and selective 5-HT 1A receptor full agonist . Pharmacology
O n July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or Kisunla, is the third drug approved to target one of the causes of ...
The U.S. Food and Drug Administration (FDA) accepted UCB's New Drug Application for lacosamide as of November 29, 2007, beginning the approval process for the drug. [43] [44] UCB also filed for marketing approval in the European Union (EU); the European Medicines Agency accepted the marketing application for review in May 2007. [43] [45]